UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

SO045 / #796 - EFFICACY AND SAFETY OF PROTON BEAM THERAPY FOR PARASPINAL CERVICAL CHORDOMA – THE INSTITUT CURIE (IC) EXPERIENCE

International journal of particle therapy, 2024-06, Vol.12

2024

Volltextzugriff (PDF)

EFFICACY AND SAFETY OF PROTON BEAM THERAPY FOR PARASPINAL CERVICAL CHORDOMA – THE INSTITUT CURIE (IC) EXPERIENCE

International journal of particle therapy, 2024-06, Vol.12, p.100357, Article 100357

2024

Volltextzugriff (PDF)

Comparison of biomarker for diagnosis of nitrous oxide abuse: challenge of cobalamin metabolic parameters, a retrospective study

Journal of neurology, 2023-04, Vol.270 (4), p.2237-2245

2023

Volltextzugriff (PDF)

FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer

Targeted oncology, 2023-03, Vol.18 (2), p.269-285

2023

Volltextzugriff (PDF)

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

Neuro-oncology (Charlottesville, Va.), 2023-01, Vol.25 (1), p.146-156

2023

Volltextzugriff (PDF)

A comprehensive map of preferentially located motifs reveals distinct proximal cis-regulatory sequences in plants

Frontiers in plant science, 2022-10, Vol.13, p.976371-976371

2022

Volltextzugriff (PDF)

Marqueurs biologiques et impact métabolique de la consommation chronique de protoxyde d’azote

Annales de biologie clinique (Paris), 2022-06, Vol.80 (3), p.209-212

2022

Volltextzugriff (PDF)

Facial Foundation

Cosmetic Dermatology, 2022, p.231-243

2022

Volltextzugriff (PDF)

Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease

The Journal of pharmacology and experimental therapeutics, 2022-03, Vol.380 (3), p.210-219

2022

Volltextzugriff (PDF)

Genotoxic impact of aluminum-containing nanomaterials in human intestinal and hepatic cells

Toxicology in vitro, 2022-02, Vol.78, p.105257-105257, Article 105257

2022

Volltextzugriff (PDF)

Availability and Integration of Agro-Environmental Data: The French Case

Landscape Agronomy, 2022, p.63-111

2022

Volltextzugriff (PDF)

A comprehensive map of preferentially located motifs reveals distinct proximal cis -regulatory elements in plants

Frontiers in plant science, 2022, Vol.13

2022

Volltextzugriff (PDF)

Abstract P204: Targeting the p300/CBP epigenetic pathway to overcome hormone therapy resistance in advanced prostate cancer

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P204-P204

2021

Volltextzugriff (PDF)

Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs

The Journal of experimental medicine, 2021-10, Vol.218 (10)

2021

Volltextzugriff (PDF)

The Courage study: A first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS5085-TPS5085

2021

Volltextzugriff (PDF)

FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice

Blood advances, 2021-05, Vol.5 (9), p.2385-2390

2021

Volltextzugriff (PDF)

Oral Administration of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Has Potent Anti-Sickling Effects in a Sickle Cell Anemia (SCA) Mouse Model, Resulting in Improved RBC Survival and Hemoglobin Levels

Blood, 2020-11, Vol.136 (Supplement 1), p.21-22

2020

Volltextzugriff (PDF)

Ex-Vivo FT-4202 Treatment Improves Hemoglobin Oxygen Affinity and Membrane Health in Red Blood Cells of Patients with Hemoglobin SS and Hemoglobin SC Disease Irrespective of Prior Hydroxyurea Use

Blood, 2020-11, Vol.136 (Supplement 1), p.23-24

2020

Volltextzugriff (PDF)

Abstract 3079: FT-6876, a potent and selective inhibitor of CBP/p300 with antitumor activity in AR-positive breast cancer

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3079-3079

2020

Volltextzugriff (PDF)

The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST

Clinical cancer research, 2020-07, Vol.26 (14), p.3751-3759

2020

Volltextzugriff (PDF)

Type I Interferon in Children with Viral or Bacterial Infections

Clinical chemistry (Baltimore, Md.), 2020-06, Vol.66 (6), p.802-808

2020

Volltextzugriff (PDF)

A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant solid tumors: Safety and efficacy as single agent

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e16643-e16643

2020

Volltextzugriff (PDF)

A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.2505-2505

2020

Volltextzugriff (PDF)

1 – 25 von 278

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Medicinal Chemistry

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(236)
Mit Volltextzugriff
(253)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(110)
Life Sciences & Biomedicine
(98)
Humans
(73)
Life Sciences
(41)
Biological And Medical Sciences
(38)
Animals
(37)
Oncology
(35)
Medical Sciences
(28)
Female
(26)
Mice
(25)
Cell Line, Tumor
(19)
Pharmacology. Drug Treatments
(19)
Biochemistry & Molecular Biology
(17)
Antineoplastic Agents
(16)
Physical Sciences
(15)
Geography
(14)
Humanities And Social Sciences
(14)
Pharmacology & Pharmacy
(14)
Tor Serine-Threonine Kinases - Antagonists & Inhibitors
(14)
Fundamental And Applied Biological Sciences. Psychology
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

SO045 / #796 - EFFICACY AND SAFETY OF PROTON BEAM THERAPY FOR PARASPINAL CERVICAL CHORDOMA – THE INSTITUT CURIE (IC) EXPERIENCE

EFFICACY AND SAFETY OF PROTON BEAM THERAPY FOR PARASPINAL CERVICAL CHORDOMA – THE INSTITUT CURIE (IC) EXPERIENCE

Comparison of biomarker for diagnosis of nitrous oxide abuse: challenge of cobalamin metabolic parameters, a retrospective study

FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

A comprehensive map of preferentially located motifs reveals distinct proximal cis-regulatory sequences in plants

Marqueurs biologiques et impact métabolique de la consommation chronique de protoxyde d’azote

Facial Foundation

Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease

Genotoxic impact of aluminum-containing nanomaterials in human intestinal and hepatic cells

Availability and Integration of Agro-Environmental Data: The French Case

A comprehensive map of preferentially located motifs reveals distinct proximal cis -regulatory elements in plants

Abstract P204: Targeting the p300/CBP epigenetic pathway to overcome hormone therapy resistance in advanced prostate cancer

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia

Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs

The Courage study: A first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer

FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice

Oral Administration of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Has Potent Anti-Sickling Effects in a Sickle Cell Anemia (SCA) Mouse Model, Resulting in Improved RBC Survival and Hemoglobin Levels

Ex-Vivo FT-4202 Treatment Improves Hemoglobin Oxygen Affinity and Membrane Health in Red Blood Cells of Patients with Hemoglobin SS and Hemoglobin SC Disease Irrespective of Prior Hydroxyurea Use

Abstract 3079: FT-6876, a potent and selective inhibitor of CBP/p300 with antitumor activity in AR-positive breast cancer

The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST

Type I Interferon in Children with Viral or Bacterial Infections

A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant solid tumors: Safety and efficacy as single agent

A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine

Aktive Filter

Suchergebnisse filtern